INTRODUCTION
============

During the development of vertebrate embryos, bone morphogenetic protein (BMP) signaling negatively regulates neural induction ([@b4-molcell-37-3-220-5]; [@b11-molcell-37-3-220-5]; [@b31-molcell-37-3-220-5]). Ectopic expression of dominant-negative BMP receptors (DNBR) or dissociation results in down-regulation of BMP signaling and leads to neural induction in ectodermal explants ([@b32-molcell-37-3-220-5]). This phenomenon is known as default neurogenesis ([@b17-molcell-37-3-220-5]). BMPs are a subfamily of the transforming growth factor beta (TGF-β) superfamily and modulate various biological processes *via* activation of Smads, most notably Smads 1/5/8 ([@b5-molcell-37-3-220-5]). During the neural induction of developing embryos, BMP signaling induces various target genes including MSX1, GATA1b and Vents, and these proteins act as neural suppressors ([@b24-molcell-37-3-220-5]; [@b25-molcell-37-3-220-5]; [@b28-molcell-37-3-220-5]). Experimentally, over-expression of these BMP target genes inhibits neural gene expression and induces epidermal fates ([@b31-molcell-37-3-220-5]). Specifically, gain-of-function studies have demonstrated that Vents participate in the inhibition of Geminin, Zic3 and Sox3 expression in the neuroectoderm ([@b23-molcell-37-3-220-5]).

Previous research has shown that the Xvent family of proteins modulates dorso-ventral specification ([@b8-molcell-37-3-220-5]; [@b9-molcell-37-3-220-5]). BMP-4 signaling directly induces the expression of Xvent and suppresses neural and dorsal mesodermal fate ([@b9-molcell-37-3-220-5]). PV.1 is a transcription factor that belongs to the Xvent gene family. PV.1 contains a homeodomain and acts as repressor *via* its C-terminal domain ([@b1-molcell-37-3-220-5]; [@b2-molcell-37-3-220-5]; [@b12-molcell-37-3-220-5]; [@b13-molcell-37-3-220-5]). Ectopic expressions in various gain-of-function studies have demonstrated that PV.1 suppresses dorsal mesodermal gene and neural gene expression, including the Chordin, Goosecoid and Zic3 genes, and induces the expression of ventral genes including wnt8 and XHox3 ([@b12-molcell-37-3-220-5]; [@b13-molcell-37-3-220-5]).

FoxD5 is a forkhead/winged helix transcription factor that functions in a variety of differentiation processes ([@b14-molcell-37-3-220-5]; [@b15-molcell-37-3-220-5]; [@b16-molcell-37-3-220-5]; [@b22-molcell-37-3-220-5]). During early *Xenopus* embryo development, FoxD5 modulates undifferentiated neural ectodermal fate and suppresses differentiation towards the neural plate in developing vertebrate embryos ([@b7-molcell-37-3-220-5]; [@b18-molcell-37-3-220-5]; [@b27-molcell-37-3-220-5]; [@b33-molcell-37-3-220-5]; [@b34-molcell-37-3-220-5]; [@b35-molcell-37-3-220-5]). The transcription of FoxD5 is regulated by various signaling pathways. For example, [@b27-molcell-37-3-220-5] reported that FoxD5 expression is up-regulated by the over-expression of Siamois and Noggin but not by the over-expression of Wnt-8 or Chordin. In our previous research, we showed that the suppression of BMP signaling induces FoxD5b expression *via* AP-1c-Jun/ FosB. Additionally, we found that the FoxD5a and b promoters have two highly conserved 5′-flanking regions. The AP-1 binding site, which is involved in the FoxD5b expression induced by the suppression of BMP signaling, is located in this conserved region. Additionally, we have previously reported that increased BMP signaling negatively regulates FoxD5b expression and that the activity of the FoxD5b promoter is reduced by increased BMP signaling; however, the detailed mechanisms of this process have remained elusive.

Here, we confirmed that FoxD5b expression is negatively regulated by BMP signaling. The over-expression of PV.1 (one of the target genes of BMP) indicated that PV.1 directly suppressed FoxD5b expression. Additionally, a promoter assay revealed that PV.1 might regulate FoxD5b expression indirectly via Hox genes. These results suggest that BMP signaling suppressed FoxD5b expression *via* the induction of its target genes.

MATERIALS AND METHODS
=====================

Embryo injection and explant culture
------------------------------------

*Xenopus* laevis embryos were obtained by artificial fertilization ([@b26-molcell-37-3-220-5]). Developmental stages were designated according to the scheme of [@b21-molcell-37-3-220-5]. RNA or DNA was injected into the animal pole of the embryos at the one-cell stage, as described in the figure legends. The animal caps were dissected from the injected embryos at stage 8 and cultured until stage 13 in 67% Leibovitz's L-15 medium (GIBCO/BRL) with BSA (1 mg/ml), 7 mM Tris-HCl (pH 7.5) and gentamicin (50 μ/ml). The cultured explants were incubated at 23°C before harvesting.

Whole mount *in situ* hybridization
-----------------------------------

Embryos were injected with mRNAs as indicated and subsequently processed for whole-mount *in situ* hybridization using standard methods with anti-sense probes for FoxD5b ([@b20-molcell-37-3-220-5]).

RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)
--------------------------------------------------------------------------

For qRT-PCR, total RNA was prepared using the TRIzol reagent (Tel-Test, Inc., USA), and cDNA was synthesized using the SuperScript pre-amplification system (Invitrogen). The PCR primers and cycling conditions are described in the *Xenopus* Molecular Marker Resource (University of Texas). Additional primers are described in Table 2. The PCR reactions were performed with SYBR Premix (Qiagen, USA) and a thermal cycler real-time system (Qiagen Rotor-Gene-Q, USA).

*In vitro* transcription
------------------------

The PV.1 and DNBR mRNAs used for microinjection were produced by *in vitro* transcription. The cDNAs for PV.1 and DNBR were inserted into the pCS2 vector. The cDNAs were linearized and used for *in vitro* synthesis of capped mRNA using an *in vitro* transcription kit (Ambion) according to the manufacturer's instructions. The synthetic RNA was quantified with ethidium bromide staining and compared to a standard RNA.

Luciferase assay
----------------

The level of luciferase activity was measured using a luciferase assay system according to the manufacturer's instruction (Promega, USA). Five or six groups of animal caps (5 animal caps per group) were harvested and homogenized in 30 μl of lysis buffer. A luminometer was used to measure 40 μl of luciferase substrate and 10 μl of whole cell lysate (Promega, USA). All experiments were repeated at least three times using independently derived sample sets.

Site-directed mutagenesis
-------------------------

Mutagenesis of -301\_(m)Hox was performed using a Site-Directed Mutagenesis Kit (Intronbio, KR) according to the manufacturer's instructions. PCR primers were (upstream) 5′-CA TCACATAGATGCGCGAGACTTAATTATTGG-3′ and (downstream) 5′-CCAATAATTAAGTCTCGCGCATCTATGTGATG-3′.

Statistical analyses
--------------------

All experiments were independently performed more than three times. The data are presented as the means ± the SEs. *T*-tests were used to compare groups *via* the GraphPad Prizm program (GraphPad Software, USA).

RESULTS
=======

Neural induction is negatively regulated by PV.1
------------------------------------------------

PV.1 is a downstream target gene of BMP signaling ([@b1-molcell-37-3-220-5]; [@b19-molcell-37-3-220-5]) and has a ventralizing effect in *Xenopus* embryos ([@b2-molcell-37-3-220-5]; [@b13-molcell-37-3-220-5]). To confirm the role of PV.1 in whole embryos, PV.1 RNAs were co-injected with beta-galactosidase into embryos in the one-cell stage. As shown in [figure 1A](#f1-molcell-37-3-220-5){ref-type="fig"}, over-expression of PV.1 dose-dependently caused ventralization and abnormal head formation. These morphological changes suggest that PV.1 reduced dorsal mesodermal and neural gene expression. Therefore, to confirm that PV.1 inhibited the expression of neural genes, RT-PCR was performed on DNBR-injected ectodermal explants. Suppression of BMP signaling by DNBR induced expression of neural genes including Zic3 and FoxD5b without inducing dorsal mesoderm. However, over-expression of PV.1 decreased the expression of the neural genes Zic3 and FoxD5b ([Fig. 1B](#f1-molcell-37-3-220-5){ref-type="fig"}). Additionally, we examined the temporal expression patterns of PV.1 and FoxD5b. PV.1 was highly expressed during the midblastula stage, and FoxD5b was also expressed from the early blastula to the mid-blastula stages ([Fig. 1C](#f1-molcell-37-3-220-5){ref-type="fig"}). An *in situ* hybridization assay showed that the over-expression of PV.1 decreased FoxD5b expression in whole embryos ([Fig. 1D](#f1-molcell-37-3-220-5){ref-type="fig"}).

Taken together, these data suggest that PV.1 regulates FoxD5b expression in blastula embryos.

PV.1 directly suppresses neural induction
-----------------------------------------

To investigate whether PV.1 directly or indirectly decreases FoxD5b expression, the transcriptional levels of FoxD5b were examined in cyclohexamide (CHX)-treated ectodermal explants by RT-PCR. As shown in [Fig. 2A](#f2-molcell-37-3-220-5){ref-type="fig"}, suppression of BMP signaling induced FoxD5b expression, but co-injection of PV.1 significantly decreased the FoxD5b expression that was induced by DNBR in the control animal cap explants. Interestingly, co-injection of DNBR and PV.1 also led to same result in the cyclohexamide-treated animal cap explants. These data suggests that PV.1 directly reduced FoxD5b expression. Additionally, we also explored whether the expression of Zic3, one of the neural-specific genes, was regulated by PV.1. Our data showed that Zic3 was also directly suppressed by PV.1 ([Fig. 2B](#f2-molcell-37-3-220-5){ref-type="fig"}). Taken together, these results suggest that PV.1 directly suppressed neural gene expression.

PV.1 negatively regulates the promoter activity of FoxD5b
---------------------------------------------------------

To investigate how PV.1 negatively regulates FoxD5b expression, a promoter assay was performed with the 5′-flanking region of the FoxD5b promoter. Over-expression of PV.1 decreased the luciferase activity of the FoxD5b promoter ([Fig. 3A](#f3-molcell-37-3-220-5){ref-type="fig"}). To identify the PV.1-response element, serial truncated FoxD5b promoters were analyzed. Our previous studies have shown that the AP-1 binding site, which acts as a positive regulatory element, is located in between -1336 and -1316. Additionally, we found that two promoter regions of FoxD5a and FoxD5b were highly conserved as shown in [Fig. 3B](#f3-molcell-37-3-220-5){ref-type="fig"}. Truncation of the AP-1 binding site in the FoxD5b promoter decreased luciferase activity because the positive regulatory element was eliminated. Interestingly, over-expression of PV.1 decreased the luciferase activity of the serially truncated FoxD5b promoter, but the activity of the -186 construct was not reduced by PV.1.

These results suggest that the PV.1 response element is located in between -301 and -186, which is a conserved region in the FoxD5 and FoxD5b promoters.

The indirect response element of the FoxD5b promoter is between -301 and -186 region
------------------------------------------------------------------------------------

We have previously shown that PV.1 negatively regulates FoxD5b expression and that the response element is located in the FoxD5b promoter between -301 and -186. Thus, we next analyzed promoter sequences to identify the Xvent/PV.1 binding site (CAAATAA) ([@b29-molcell-37-3-220-5]). However, the putative Vent/PV.1 binding site was not present, and chromate immunoprecipitation (ChIP) analysis also demonstrated that PV.1 could not bind in this region (data not shown). To confirm if the PV.1 response element is present in the region between -301 and -186, the expression of the luciferase gene, which is encoded by the FoxD5b promoter, was measured using cyclohexamide-treated animal cap explants and RT-PCR. As shown in [Fig. 4A](#f4-molcell-37-3-220-5){ref-type="fig"}, the expression level of luciferase mRNA, which is encoded by the FoxD5b promoter, was increased by the DNBR. Co-injection of PV.1 with DNBR decreased luciferase expression in the DMSO-treated animal cap explants. However, over-expression of PV.1 did not change the expression of the luciferase gene in the cyclohexamide-treated animal cap explants. These results suggest that our FoxD5b promoter construct did not contain the direct PV.1 regulatory element; rather the indirect regulatory response element exists in this region. Interestingly, we found a putative Hox binding site in the region between -301 and -186.

Hox genes are also BMP-target genes and are involved in ventral fate specification ([@b30-molcell-37-3-220-5]). Thus, we generated the a -301\_(m)Hox construct that contained a mutation in the Hox binding site. We compared the promoter activity of -301 and -301\_(m)Hox in whole embryos as indicated in [Fig. 4C](#f4-molcell-37-3-220-5){ref-type="fig"}. The decreased reporter activity of the wild type promoter by PV.1 was not found when -301-(m)Hox was co-injected with PV.1. Thus, our data suggest that the putative Hox binding site mediates the suppression of FoxD5b expression due to the over-expression of PV.1. Additionally, the over-expression of PV.1 revealed that the expression of some Hox genes, includeing HoxB4 and HoxC6, were increased ([Fig. 4D](#f4-molcell-37-3-220-5){ref-type="fig"}).

Taken together, we interpret our data to suggest that the suppression of FoxD5b expression by PV.1 may be mediated by a Hox gene.

DISCUSSION
==========

BMP signaling is involved in various cell fate specification in of vertebrate embryogenesis ([@b5-molcell-37-3-220-5]; [@b6-molcell-37-3-220-5]; [@b10-molcell-37-3-220-5]; [@b11-molcell-37-3-220-5]; [@b31-molcell-37-3-220-5]). During the early development of *Xenopus* embryos, BMP signaling gradients modulate dorso-ventral patterning and negatively regulate neural induction ([@b6-molcell-37-3-220-5]). The Spemann's organizer, which is located in the dorsal mesoderm, produces BMP antagonists and reduces BMP signaling ([@b11-molcell-37-3-220-5]). The suppression of BMP signaling induces neural fate in the ectoderm ([@b32-molcell-37-3-220-5]). BMP signaling induces numerous target genes including MSX1, Vents and GATAs, which can inhibit neural gene expression ([@b3-molcell-37-3-220-5]; [@b9-molcell-37-3-220-5]; [@b13-molcell-37-3-220-5]; [@b23-molcell-37-3-220-5]; [@b25-molcell-37-3-220-5]; [@b28-molcell-37-3-220-5]). However, the mechanism by which BMP signaling suppresses neural induction is not fully understood.

Our previous research has shown that the FoxD5a and FoxD5b promoters have two highly conserved regions. The suppression of BMP signaling induces FoxD5b expression through AP-1c-Jun/FosB. Interestingly, the AP-1 binding site is a conserved region. Furthermore, we also found that the over-expression of BMP4 strongly reduced the activity of the FoxD5b promoter in the entire embryo (data not shown). These data suggest that the FoxD5b promoter has a negative response element that is regulated by BMP signaling.

PV.1 has roles in ventralization and inhibition of neural induction that are mediated by BMP signaling *via* its c-terminal repressor domain ([@b13-molcell-37-3-220-5]). Here, we investigated how PV.1 regulates the expression of FoxD5b, which is an early neural gene. PV.1 and FoxD5b are highly expressed in the blastula stage. Over-expression of PV.1 reduced FoxD5b expression and the promoter activity of FoxD5b. These results are consistent with the phenotypical changes of the whole embryos. Additionally, we analyzed whether PV.1 directly suppressed FoxD5b expression using a cyclohexamide treatment. As shown in [Figs. 2A](#f2-molcell-37-3-220-5){ref-type="fig"} and [2B](#f2-molcell-37-3-220-5){ref-type="fig"}, PV.1 directly suppressed FoxD5b and Zic3 expression. The luciferase assay with serially truncated FoxD5b promoters demonstrated that the PV.1 response element is located between -301 and -186. However, no putative binding site was found in this region. A ChIP assay also revealed that PV.1 did not interact at this region (data not shown). Furthermore, we analyzed the expression of the luciferase gene for the FoxD5b promoter in cyclohexamide-treated animal cap explants ([Fig. 4A](#f4-molcell-37-3-220-5){ref-type="fig"}). These results suggest that our FoxD5b promoter did not contain a direct response element for PV.1. Sequence analysis of theFoxD5b promoter using bioinformatics revealed that a putative Hox binding site exists in the -301 region. Hox family genes have been known to regulate dorsoventral and anterioposterior patterning *via* the mediation of BMP signaling during the early development of vertebrate embryos. Additionally, our results showed that the over-expression of PV.1 increased the expression of several Hox genes ([Fig. 4D](#f4-molcell-37-3-220-5){ref-type="fig"}). Furthermore, a point mutation of the putative Hox binding in the -301 construct demonstrated that the putative Hox binding site is involved with FoxD5b expression, which is regulated by PV.1. Taken together, we suggest that some Hox genes cooperatively regulate FoxD5b expression with PV.1. However, which Hox genes participate in this process is still unclear.

Although the over-expression of BMP downstream target genes, including MSX1, GATA and Vents, is sufficient for the suppression of neural fate, no data exists that suggests that the knock-down of these genes induces neural tissue. In this study, we also examined whether the knock down of PV.1 induced neural induction. The micro-injection of PV.1 morpholino oligos slightly increased the expression of Zic3 and FoxD5b at stage 10, but these treatments did not induce any neural marker at stage 24. This result indicates that the knock-down of PV.1 alone was not sufficient to induce neurogenesis. In other words, PV.1 and some BMP down-stream target genes cooperatively suppress the neural gene expression.
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![PV.1 suppresses neural gene expression. (A) PV.1 RNAs of PV.1 was injected as indicated at the one-cell stage. Phenotypical changes were observed at stage 33. DAI means the dorso- anterior index. (B) PV.1 (500 pg) was either injected alone or co-injected with DNBR (1 ng) at the one-cell stage. Animal cap explants were dissected at stage 8, incubated until stage 10 and then RT-PCR was performed for the analysis of relative gene expression. ODC, loading control; noRT, control reaction without reverse transcriptase; WE, Whole embryo as a positive control; chordin, Dorsal mesodermal marker; Xbra, mesodermal marker; FoxD5b and Zic3, early neural marker. (C) The temporal expression pattern of FoxD5b and PV.1 were analyzed using RT-PCR at various developmental stages as indicated. (D) PV.1 RNAs were injected into one side of each of the two cell embryos. These embryos were processed for whole mount *in situ* hybridization with anti-sense probe of FoxD5b at stage 10. The injected side of the embryos is indicated by *Beta*-gal staining. The blue dotted line indicates the dorsal lip.](molcell-37-3-220-5f1){#f1-molcell-37-3-220-5}

![PV.1 reduces FoxD5b and Zic3 expression. (A, B) Embryos were injected with RNAs (PV.1, 500 pg and DNBR, 1 ng) at the one-cell stage as indicated. Animal explants were dissected at stage 8 and incubated in the animal cap media containing DMSO or cyclohexamide (CHX, 5 ng/ml) until stage 10. RT-PCR was performed to analyze the relative FoxD5a and Zic3 expressions. Data are shown as the means ± the S.D. of the values from at least 3 independent experiments. Differences were considered significant at *P* \< 0.05.](molcell-37-3-220-5f2){#f2-molcell-37-3-220-5}

![PV.1 reduces the promoter activity of FoxD5b. (A) Embryos were co-injected with the -1336 construct (20 pg) and PV.1 (500 pg) at the one-cell stage and incubated until stage 10. Luciferase activity was measured as described in the "Materials and Methods". (B) The graph shows regions of high similarity based upon the NCBI-BLAST results. (C) Schematic representation of the serially truncated FoxD5b promoter constructs. (D) The embryos were injected with FoxD5b promoter alone or with PV.1 as indicated. Luciferase activities were measured at stage 10. The data are shown as the means ± the S.D. of the values from at least three independent experiments. Differences were considered significant at *P* \< 0.05.](molcell-37-3-220-5f3){#f3-molcell-37-3-220-5}

![PV.1 regulates FoxD5b expression indirectly *via* the putative Hox binding site. (A) Embryos were co-injected -1336 construct with RNAs (PV.1, 500 pg and DNBR, 1 ng) at the one-cell stage as indicated. Embryos were harvested at stage 10 for analyses of the relative luciferase gene expressions using RT-PCR. (B) Schematic representation of -301\_(m)Hox construct (C) The -301 or -301\_(m) Hox constructs were either injected alone or co-injected with PV.1 at the one-cell stage. Luciferase activity was measured at stage 10. (D) RNAs of PV.1 (500 pg) were injected at the one-cell stage. Animal caps were dissected at stage 8 and incubated until stage 10. RT-PCR was performed for the analysis of the expression of the indicated genes. The data are shown as the means ± the S.D.s of the values of at least three independent experiments. Differences were considered significant at *P* \< 0.05.](molcell-37-3-220-5f4){#f4-molcell-37-3-220-5}

[^1]: These authors contributed equally to this work.
